Latest Insights & News
View All Articles →Vera Atacicept: TACI-Fc BAFF+APRIL dual. ORIGIN Ph2b 36-wk UPCR -35% PBO-adj; ORIGIN 3 (NEJM 2026, n=203 interim) -41.8pp. PDUFA Jul 7, 2026.
Vertex's Inaxaplin (VX-147) blocks variant APOL1 channels. Phase 2a (NEJM 2023): UPCR −47.6%. AMPLITUDE Ph2/3 targets accelerated approval in APOL1-MKD.
Novartis Atrasentan (Vanrafia): ETA-selective IgAN drug. ALIGN UPCR -36.1% FDA accelerated 2025. Week 136 eGFR +2.39 p=0.057; 2026 traditional filing.
MASH (Diet-Induced)
CCl4-Induced Liver Fibrosis
Bleomycin-Induced Pulmonary Fibrosis
UUO Mouse Model
Bleomycin-Induced Scleroderma
DSS-Induced Colitis
Browse by Disease Area
Find preclinical models for your indication
Liver / Hepatic
MASH/NASH, CCl₄, MCD, and other liver fibrosis models
View models →Lung / Pulmonary
Bleomycin-induced IPF, silica, and other pulmonary fibrosis models
View models →Kidney / Renal
UUO, adenine nephropathy, ADR/FA, and other CKD progression models
View models →Heart / Cardiac
Myocardial infarction, pressure-overload, and cardiac fibrosis models
View models →Skin / Dermal
Bleomycin SSc, hypochlorite, and systemic sclerosis models
View models →GI / Inflammatory Bowel
DSS colitis, TNBS, and chronic IBD/fibrosis models
View models →For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.